-- Valeant Reports 41% Increase in Second-Quarter Revenue
-- B y   T i m   F a r r a n d
-- 2013-08-07T10:36:41Z
-- http://www.bloomberg.com/news/2013-08-07/valeant-reports-41-increase-in-second-quarter-revenue.html
Valeant Pharmaceuticals International
Inc. (VRX)  raised its forecast for full-year earnings after posting a
41 percent increase in second-quarter revenue.  Valeant estimates 2013 adjusted earnings per share of $6 to
$6.20, up from a prediction in May of $5.55 to $5.85. Second-quarter revenue excluding one-time items rose to $1.1 billion,
the company said today in a statement.  Cash earnings per share increased 54 percent, excluding
one-time items, in the second-quarter to $1.34, the company
said. Analysts had estimated an EPS of $1.28, according to a
survey compiled by Bloomberg.  To contact the reporter on this story:
Tim Farrand in Edinburgh at 
 tfarrand@bloomberg.net   To contact the editor responsible for this story:
David Risser at 
 drisser@bloomberg.net  